VHH Antibody Applications
From Robust Tools to Complex Therapeutics
Versatile formats and validated workflows for CAR-T, Bi-specifics, ADCs, and more. See Applications
Isogenica’s synthetic, humanized VHH antibodies offer flexible, high-performance solutions across a growing range of therapeutic and diagnostic applications. Their small size, stability, and binding precision make them ideal for applications where conventional antibodies fall short – from CAR-T and Bi-specifics to ADCs, intracellular targets, and robust tools.
Backed by modular technologies and a peer-level partnership model, Isogenica helps biotech teams design, screen, and optimize candidates faster and with greater confidence.
Bi-Specific Antibodies
The small size and modularity of VHHs enable versatile bi– or multi–specific designs where you control valency, linker length, and more. Isogenica’s platform supports parallel discovery of high-affinity binders for dual-target formats, with early data to guide pairing and optimization.
Antibody Conjugate and ADC Applications
VHHs are versatile can be used to target any number of payloads to a biological target – this includes small molecules (ADC), oligonucleotides (AOC), radionuclides (ARC), as well as large carriers such as LNPs or viral particles. Our suite of conjugation handles can be included from the very earliest stages of VHH discovery.
CAR-T and Cell Therapy
VHHs offer a compact, stable, and clinically validated alternative to scFvs in CAR-T constructs – reducing aggregation and T-cell exhaustion while improving expression and manufacturability. Isogenica’s synthetic libraries provide high-specificity VHHs suitable for targeting tumor-associated antigens.
Agonists & Antagonists
VHHs can act as direct modulators of target activity, with high specificity and adaptable valency. Isogenica’s partnership with Axxam further supports agonist discovery through early high-throughput screening in functional cell assays.
Work with us
By partnering with our expert team, you’ll not only benefit from access to our state-of-the-art technology and expertise but also the perks of how we like to work with others. From start to finish we become an extended part of your team, keeping you updated and informed regularly on our progress. With our groundbreaking technology and expert guidance, Isogenica helps small to mid-sized biotech companies bring novel therapies to market faster— cutting typical discovery timelines in half by accelerating lead selection and reducing follow-on engineering requirements. Talk to us today and find out how we can accelerate your VHH discovery project.